|
Specially commissioned lectures by leading world experts.
The Biomedical & Life Sciences Collection
New Releases for November
|
|
|
|
This month’s release to The Biomedical & Life Sciences Collection features talks by academic and industry experts on parasitic diseases, weight management, gene therapies, human microbiota, and much more.
In the Periodic Reports: Advances in Clinical Interventions and Research Platforms series, Professor Robert Zeiser, University of Freiburg (Germany), presents the talk ‘Targeting the intestinal barrier in GVHD and checkpoint colitis’. Prof. Zeiser has translated multiple therapeutic approaches from the mouse model into a clinical application in the fields of GVHD and leukaemia immunotherapy. In this talk he discusses the complex inflammatory mechanisms underlying intestinal GVHD, the limitations of corticosteroid treatment and the evidence supporting second-line therapies.
Also taking place later this month is the next event in our live webinar series, on ‘Immune balance, the thymus and healthy aging’. Dr. Robert Striker, University of Wisconsin-Madison (USA), and Dr. Yolanda M. Pacheco, Instituto de la Grasa (Spain), will explore how age-related changes in thymic function affect immune health and resilience. The discussion will focus on key immune biomarkers, particularly CD4 counts and the CD4/CD8 ratio, and how these can help assess disease risk, inform clinical decisions and guide interventions to support healthy ageing. This free event will take place on Tuesday 24th November 2026 at 5pm GMT / 12pm EST / 9am PST, register to attend here.
Kind regards,
The Editorial Team
|
|
|
|
New Series: Developing Gene Therapies
|
|
|
Gene therapies: economics, access barriers & commercial models
Dr. Kasem S. Akhras
VantEdge Access LLC, USA
|
|
|
|
|
|
Regulatory considerations in the development of gene therapy products
Dr. Seoan Huh
Eli Lilly and Company, USA
|
|
|
|
|
|
Long-term follow-up of gene therapy trial participants: practical and statistical considerations
Dr. Avery McIntosh
Pfizer, USA
|
|
|
|
|
More New Releases
|
|
|
Targeting the intestinal barrier in GVHD and checkpoint colitis
Prof. Robert Zeiser
Medical Center – University of Freiburg, Germany
|
|
|
|
|
|
Parasitic diseases: causes, mechanisms, and clinical examples
Prof. Hany Elsheikha
University of Nottingham, UK
|
|
|
|
|
|
Pathophysiology of type 1 and type 2 diabetes
Prof. Karim Meeran
Imperial College London, UK
|
|
|
|
|
|
The environment & scleroderma
Dr. Zsuzsanna McMahan
McGovern Medical School, UTHealth Houston, USA
|
|
|
|
|
|
New standards in weight management
Prof. John Wilding
University of Liverpool, UK
|
|
|
|
|
|
Evolutionary perspectives on human microbiota: a journey through zoological and bacteriological realms
Prof. Gabriel Trueba
San Francisco de Quito University, Ecuador
|
|
|
|
|
|
Bioavailability of micronutrients (minerals and vitamins)
Prof. Susan Fairweather-Tait
University of East Anglia, UK
|
|
|
|
|
|
Vitamin D
Prof. Susan Fairweather-Tait
University of East Anglia, UK
|
|
|
|
|
|
The olfactory system
Prof. Adam Dewan
Florida State University, USA
|
|
|
|
|
|
The human microbiome in health & disease
Dr. Martin Goldberg
Birmingham City University, UK
|
|
|
|
|
|
Microbes and disease
Dr. Martin Goldberg
Birmingham City University, UK
|
|
|
|
|
|
Mucosal vaccine adjuvants
Dr. Sivakumar S. Moni
Jazan University, Saudi Arabia
|
|
|
|
|
|
Natural ligands of nuclear receptors
Prof. Dr. Daniel Merk
Ludwig-Maximilians-University (LMU), Germany
|
|
|
|
|
|
Nuclear receptor targeting drugs
Prof. Dr. Daniel Merk
Ludwig-Maximilians-University (LMU), Germany
|
|
|
|
|
|
Peroxisome proliferator-activated receptors: PPARγ (NR1C3) – biological role and drugs
Prof. Dr. Daniel Merk
Ludwig-Maximilians-University (LMU), Germany
|
|
|
|
|
|
Navigating the FDA roadmap for new approach methodologies
With Experts from Roche, Eli Lilly, Genentech and InSphero
|
|
|
|
|
New Interviews
|
|
|
Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer
Prof. Sacha Gnjatic
Icahn School of Medicine at Mount Sinai, USA
|
|
|
|
|
|
Optimising collaboration between lead identifiers and genomic analysts in pharma and biotech companies
Dr. Fritz Sedlazeck
Baylor College of Medicine, USA
|
|
|
|
|
|
Complex in vitro models and the future of drug safety and efficacy assessment
Dr. Nadine Stokar-Regenscheit
Roche, Switzerland
|
|
|
|
|
Featured talks from previous releases
|
|
|
|
|
|
|
|
For assistance, contact HSTalks subscriber support:
Subscriber Support, Henry Stewart Talks Ltd
Tel: +44 (0) 20 7092 3480, Email: access@hstalks.com
|
|
For more specially commissioned lectures:
|
